# A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

> **NCT06481475** · PHASE2 · RECRUITING · sponsor: **Chongqing Claruvis Pharmaceutical Co., Ltd.** · enrollment: 174 (estimated)

## Conditions studied

- Moderate to Severe Glabellar Lines

## Interventions

- **BIOLOGICAL:** YY003
- **BIOLOGICAL:** Vehicle Control

## Key facts

- **NCT ID:** NCT06481475
- **Lead sponsor:** Chongqing Claruvis Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-09
- **Primary completion:** 2025-07
- **Final completion:** 2025-10
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06481475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06481475, "A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06481475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*